Absence of Changes in Galectin-3 with Insulin Sensitization and Anti-inflammation
| Autor: | Husam Ghanim, Ajay Chaudhuri, Paresh Dandona, Manasi Shah, Antoine Makdissi, Kelly Green |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
business.industry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment Anti inflammation medicine.disease Morbid obesity Insulin resistance Endocrinology medicine.anatomical_structure Galectin-3 Weight loss Internal medicine Internal Medicine medicine In patient medicine.symptom business Sensitization |
| Zdroj: | Diabetes. 67 |
| ISSN: | 1939-327X 0012-1797 |
| DOI: | 10.2337/db18-1771-p |
| Popis: | Galectin-3 (gal-3) has recently been shown to mediate insulin resistance in mice. Its deletion leads to insulin sensitization while its excess is associated with insulin resistance. We, thus, undertook an investigation into its role in the reversal of insulin resistance in three human models of insulin sensitization: (1) 6 months following bariatric surgery (RYGB) and weight loss in patients with morbid obesity; there was a reduction in BMI from 52.1±4.8 to 40.4±4.0 kg/m2 (p Disclosure P. Dandona: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca. H. Ghanim: None. M.S. Shah: None. K. Green: None. A. Makdissi: Speaker's Bureau; Self; Eli Lilly and Company. A. Chaudhuri: Speaker's Bureau; Self; AstraZeneca, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc.. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|